Aldeyra Therapeutics (NASDAQ:ALDX) Stock Rating Lowered by StockNews.com

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) was downgraded by equities researchers at StockNews.com from a "hold" rating to a "sell" rating in a report issued on Monday.

A number of other research firms have also commented on ALDX. Oppenheimer reissued an "outperform" rating and issued a $10.00 price target on shares of Aldeyra Therapeutics in a research report on Monday. HC Wainwright reiterated a "buy" rating and issued a $10.00 target price on shares of Aldeyra Therapeutics in a report on Monday.

Aldeyra Therapeutics Stock Performance

Shares of ALDX stock traded down $0.04 during trading hours on Monday, hitting $4.12. 305,625 shares of the company were exchanged, compared to its average volume of 565,127. The firm has a market cap of $244.77 million, a P/E ratio of -8.08 and a beta of 1.45. The company has a 50 day simple moving average of $3.71 and a two-hundred day simple moving average of $3.22. Aldeyra Therapeutics has a fifty-two week low of $1.42 and a fifty-two week high of $11.97.

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last issued its earnings results on Thursday, March 7th. The biotechnology company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.21) by $0.13. As a group, sell-side analysts expect that Aldeyra Therapeutics will post -0.14 EPS for the current fiscal year.

Insider Activity

In other news, major shareholder Perceptive Advisors Llc purchased 8,374 shares of the business's stock in a transaction on Monday, April 1st. The stock was purchased at an average cost of $3.25 per share, with a total value of $27,215.50. Following the acquisition, the insider now directly owns 8,601,960 shares in the company, valued at $27,956,370. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. In other news, CEO Todd C. Brady sold 97,914 shares of the business's stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $3.27, for a total transaction of $320,178.78. Following the completion of the transaction, the chief executive officer now owns 1,556,622 shares of the company's stock, valued at $5,090,153.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Perceptive Advisors Llc acquired 8,374 shares of the stock in a transaction dated Monday, April 1st. The shares were bought at an average price of $3.25 per share, for a total transaction of $27,215.50. Following the transaction, the insider now owns 8,601,960 shares in the company, valued at approximately $27,956,370. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 355,933 shares of company stock worth $1,473,245. 7.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On Aldeyra Therapeutics

Institutional investors have recently modified their holdings of the company. Allspring Global Investments Holdings LLC purchased a new position in Aldeyra Therapeutics in the 3rd quarter worth $124,000. Hennion & Walsh Asset Management Inc. boosted its holdings in Aldeyra Therapeutics by 89.5% during the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 73,669 shares of the biotechnology company's stock valued at $492,000 after acquiring an additional 34,796 shares during the period. Fox Run Management L.L.C. bought a new position in Aldeyra Therapeutics during the 3rd quarter worth approximately $224,000. Barclays PLC increased its stake in Aldeyra Therapeutics by 9.0% in the 3rd quarter. Barclays PLC now owns 138,311 shares of the biotechnology company's stock worth $924,000 after purchasing an additional 11,447 shares during the period. Finally, Citigroup Inc. lifted its position in Aldeyra Therapeutics by 34.6% in the third quarter. Citigroup Inc. now owns 113,036 shares of the biotechnology company's stock valued at $755,000 after purchasing an additional 29,031 shares during the last quarter. 59.71% of the stock is currently owned by institutional investors.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.